

conferenceseries.com

Tentative Program

29th International Conference on

Vaccines and Immunization

London, UK March 19-20, 2018

Theme: "Highlights of latest technologies and innovations in Vaccines and Immunization"

Interactive Sessions | Keynote Lectures | Plenary Lectures | Workshops | Exhibitors | B2B Meetings

For available speaker slots

vaccinessummit@conferenceseries.net

conferenceseries.com

Tentative Program

29th International Conference on

Vaccines and Immunization

London, UK March 19-20, 2018

Program at A Glance

Day 1

Morning Sessions	**Reception/Registration**	**08:00-09:00**	
		Time	**General Session**
		09:00-09:15	Inaugural Address
	Least of 3 Keynote/Plenary Talks	09:15-09:45	Keynote/Plenary Talk 1
		09:45-10:15	Keynote/Plenary Talk 2
		10:15-10:45	Keynote/Plenary Talk 3
	Panel Discussions/Group Photo		
	Coffee/Tea Break 10:45-11:00 (Networking)		
Evening Sessions	11:00-12:40	5 Speakers (20 Mins Each)	
	Lunch Break 12:40-13:30		
	13:30-15:30	5 Speakers (20 Mins Each)	
	Coffee/Tea Break 15:30-15:45 (Networking)		
	15:45-17:25	5 Speakers (20 Mins Each)	

Day 2

	Time	**Session 1**	**Session 2**
Morning Sessions	09:00-10:40	Keynote Forum	
	Coffee/Tea Break 10:40-10:55 (Networking)		
	10:55-12:35	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Lunch Break 12.35-13.25		
Evening Sessions	13:25-15:05	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Coffee/Tea Break 15.05-15.20 (Networking)		
	15.20-17.00	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Awards & Closing ceremony		

NOTE: Program Schedule is subject to change with final allotment of the speaker slots

For more Details: www.vaccines-immunization.conferenceseries.com

vaccinessummit@vaccinesconference.com | vaccinessummit@vaccinesconference.net

Conference Highlights

- Human Vaccines against Infectious Diseases
- Cancer, Malaria & TB Vaccines
- HIV Vaccines
- Immunizations & Bioterrorism
- Combination & Conjugate Vaccines
- DNA & Synthetic Vaccines
- Travel & Edible Vaccines
- Paediatric Vaccination
- Vaccines for Immune Mediated Diseases
- Veterinary Vaccines
- Fish & Poultry Vaccines
- Vaccines against Drugs
- Vaccines & Autism
- Vaccine Safety & Efficacy
- Geriatric Immunization
- Vaccines for Pregnant Women & Neonates
- Vaccines for Unconventional Diseases
- Animal Models & Clinical Trails
- Animal & Plant Derived Vaccines
- Vectors, Adjuvants & Delivery Systems
- Vaccine Production & Development
- Cellular Immunology & Latest Innovations
- Antibodies: Engineering & Therapeutics
- Current Research & Future Challenges

Best Poster Award

- You will be given about 5-7 minutes to present your poster including questions and answers. Judges may pose questions during the evaluation of the poster
- Judges will even evaluate the student's enthusiasm towards their study, interest and knowledge in the area of their research
- The winners will be announced at the closing ceremony of the conference. The decision of the winner will be withdrawn if the winner/winners is/are not present at the time of announcement
- Apart from the judging time you may also be present at the poster to share your research with interested delegates

Young Researchers Forum

- Present your research through oral presentations
- Learn about career development and the latest research tools and technologies in your field
- This forum will give pertinent and timely information to those who conduct research and those who use and benefit from research
- Develop a foundation for collaboration among young researchers
- The forum will provide an opportunity for collegial interaction with other young investigators and established senior investigators across the globe
- Interact and share ideas with both peers and mentors

Call for Abstract: http://vaccines-immunization.conferenceseries.com/call-for-abstracts.php

Abstract Submission: http://vaccines-immunization.conferenceseries.com/abstract-submission.php

Registration: http://vaccines-immunization.conferenceseries.com/registration.php



Glimpses


FDA
gsk
inovio
Kansas State University




conferenceseries.com
Vaccines and Immunization


conferenceseries.com


20-21, 2017
BERLIN, GERMANY
conferenceseries.com


inovio
Kansas State University
CIVS
allied


Vaccines & Vaccination



Best Tourist Destinations in London,UK



Big Ben



Buckingham Palace



HMS Belfast



Imperial War Museum



London Bridge



London Eye



Palace of Westminster



Sea Life Aquarium

About London

London is the capital and most crowded city of England and the United Kingdom. Remaining on the River Thames in the south east of the island of Great Britain, London has been a noteworthy settlement for two centuries. It was established – most likely proximate to an as of now subsisting Celtic Briton town or settlement – around the year 43 by the Romans, who assigned it Londinium. London's age-old center, the City of London, to a great extent holds its 1.12-square-mile (2.9 km2) medieval limits. Since at any rate the nineteenth century, "London" has furthermore alluded to the city around this center, truly part between Middlesex, Essex, Surrey, Kent, and Hertfordshire, which today to a great extent makes up More prevalent London, represented by the Mayor of London and the London Assembly.

London is the leading global city in arts, commerce, finance, fashion, education technology, healthcare, media, transport, tourism, research, and development. London is the global centre for Higher Education and research. According to QS World University Ranking, it has the highest number of international students. It is world's second most Economical powerful city and has the fifth- or sixth-largest metropolitan area GDP in the world. London is the world's leading investment destination, which hosts more number of international retailers and ultra high-net-worth individuals. It has world's largest city Airport System measured by passenger traffic. It is the world's most visited city measured by international arrivals. London's wetland areas support nationally important populations of many water birds. London is the home for many wildlife reserves, two National Nature Reserves and 76 Local Nature Reserves, and 38 Sites of Special Scientific Interest (SSSIs). In 2012, London turned into the main city to have facilitated the present day Summer Olympic Games three times.

The presence of universities, hospitals, labs and other professional services, together with key installations of the U.K. make it favourite destination for scientific meetings.

Important Dates

Abstract submission opens: March 22, 2017
Registration opens: March 22, 2017
Early bird registration: August 25, 2017
On spot registration: March 19, 2018

Contact Details:

Abby Olivia
Ph: (702) 508-5200 Ext: 8041
Customer Service: +1 (800) 216 6499
Email: vaccinessummit@conferenceseries.net

conferenceseries.com
888th Conference

Scientific Program

15th Annual Summit on

Vaccines and Immunization

February 20-21, 2017 Berlin, Germany



Hosting Organizations: Conference Series LLC
2360 Corporate Circle., Suite 400 Henderson, NV 89074-7722, USA
Ph: +1-702-508-5192, Fax: +1-650-618-1417, Toll free: +1-800-216-6499

Conference Series Ltd
Heathrow Stockley Park Lakeside House, 1 Furzeground Way, Heathrow, UB11 1BD, UK, Tel: +1-800-216-6499
Email: vaccinessummit@conferenceseries.net, vaccinessummit@vaccineconference.com

Registrations

Sylt 1-2

conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Title: The VCG platform facilitates mucosal and systemic vaccine delivery for induction of protective immunity in the female genital tract

Francis Eko, Morehouse School of Medicine, USA

Title: From human vaccines for viral diseases to those ones for oncogenic viruses and tumor antigens

Giulio Tarro, Foundation de Beaumont Bonelli for Cancer Research, Italy

Coffee Break

Sessions:

Vaccine Delivery Systems and Adjuvants | Vaccine Production and Delivery Technologies | Hepatitis, HIV and STD Vaccines | Vaccination for Emerging and Re-emerging Diseases | Cancer Vaccines

Session Chair: Giulio Tarro, Foundation de Beaumont Bonelli for Cancer Research, Italy
Session Co-chair: Yusuf Omosun, Morehouse School of Medicine, USA

Session Introduction

Title: VCG modulate innate and adaptive immunity to vaccine antigens
Yusuf Omosun, Morehouse School of Medicine, USA
Title: The emerging role of ASC in dendritic cell metabolism and function during *chlamydia* infection
Qing He, Morehouse School of Medicine, USA
Title: The use of new adjuvants and VLPs for the development of vaccines for emerging and infectious diseases
Gustavo Cabral de Miranda, University of Oxford, UK
Title: Pulmonary delivery of a mucosal nanocarrier vaccine for Pneumonia
Imran Saleem, Liverpool John Moores University, UK

Group Photo

Lunch Break

Session Chair: Francis Eko, Morehouse School of Medicine, USA
Session Co-chair: Talin Barissani-Asenbauer, Medical University of Vienna, Austria

Session Introduction

Title: Next-generation millisecond manufacture of genetic vaccines and lipid/polymer-based vaccines
Nadia Tagnaouti, Precision NanoSystems Inc., Canada
Title: A reasonable hope to cure HIV with the Tat Oyi vaccine: Results and follow up of a double blinded randomized phase I/IIa clinical trial in France
Erwann Loret, Aix Marseille University, France
Title: Evaluation of nanoparticle-delivered inactivated whole antigen against *Chlamydia psittaci* infection in SPF chickens
Cheng He, China Agricultural University, China
Title: Mucosal Immunization via conjunctiva: Where do we stand?
Talin Barissani-Asenbauer, Medical University of Vienna, Austria
Title: Use of corpuscular adjuvants for ocular mucosal immunization as a strategy for vaccine against trachoma
Aleksandra Inic-Kanada, Center of Ocular Inflammation and Infection, Austria

Coffee Break

Title: VVX001- a promising novel hepatitis B vaccine candidate
Rainer Henning, Viravaxx AG, Austria

Panel Discussion

End Of Day 1

Sylt 1-2

Keynote Forum

Introduction

Title: Conjugate rPA-PGA anthrax vaccine induces protective antibodies

Lallan Giri, Biologic Resources LLC, USA

Title: Development of vaccines using genetically engineered *Inoviruses*

Leondios G Kostrikis, University of Cyprus, Cyprus

Coffee Break

Sessions:

Biodefense Vaccine against Bioterrorism | Vaccines for Immune Mediated Diseases | Vaccines for Pregnant Women and Neonates | Antibodies : Engineering and Therapeutics | Animal Models and Clinical Trials

Session Chair: Leondios G Kostrikis, University of Cyprus, Cyprus
Session Co-Chair: Lallan Giri, Biologic Resources LLC, USA

Session Introduction

Title: Protection against bioterrorism
Lallan Giri, Biologics Resources LLC, USA
Title: When funding for medical countermeasures against rare, but detrimental agents is cost-effective
Mark Lawrence Johnson, MJ Lawrence Consulting, Germany
Title: An mRNA-based vaccine technology for next generation prophylactic vaccines
Susanne Rauch, CureVac, Germany
Title: ATMP Cell Therapy: Triumphs and constraints for unmet clinical needs
Shreemanta K Parida, Justus-Liebig University, Germany

Lunch Break & Poster Session

Title: Efficient expression of porcine circovirus type 2 virus-like particles in *Escherichia coli*
Guanggang Qu, Shandong Binzhou Animal Science and Veterinary Medicine Academy, China
Title: Comparison of susceptibility to measles in preterm infants versus term infants
Joseph L Mathew, Postgraduate Institute of Medical Education and Research, India
Title: Vaccines for key unmet Medical (Infectious Disease) needs in the developing world: Learning and reflections from the India Polio eradication success story
Aamir Shaikh, Assansa, India
Title: *Pneumococcal meningoencefalitis* in 50-day-old baby ended with lethal outcome: A case report
Liliya Pekova, University hospital (Stara Zagora), Bulgaria
Title: Promising results in the assessment of new vaccine candidates against *campylobacter* in poultry
Marine Meunier, French Agency for Food, Environmental and Occupational Health & Safety, France

Coffee Break

Panel Discussions

End Of Day 2

Closing Ceremony

conferenceseries.com

Scientific Program

10th Euro Global Summit and Expo on

Vaccines & Vaccination

June 16-18, 2016 Rome, Italy



Hosting Organization: Conference Series LLC

2360 Corporate Circle, Suite 400 Henderson, NV 89074-7722, USA **Ph:** +1-702-508-5200 Ext: 8047, **Toll free:** +1-800-216-6499

e-mail: eurovaccines@insightconferences.com; eurovaccines@conferenceseries.net

Registrations

Appia

conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Title: Development of the full length single chain gp120-CD4 (FLSC), a novel vaccine for HIV prevention
Timothy R Fouts, Profectus Biosciences Inc., USA

Title: Vaccines moving beyond the next frontier
Rene Labatut, Sanofi Pasteur, France

Networking & Refreshments Break

Title: VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo-controlled phase 2b study
Prakash Bhuyan, Inovio Pharmaceuticals, USA

Group Photo

Track 1: Cancer Vaccines
Track 2: Vaccine Products and Delivery Technologies
Track 3: Vaccine Research and Development
Track 4: Vaccines for Respiratory Infections
Track 5: HIV Vaccines
Track 6: Veterinary vaccines

Session Chair: **Timothy R Fouts,** Profectus Biosciences Inc., USA
Session Co-chair: **Qingsheng Li,** University of Nebraska-Lincoln, USA

Session Introduction

Title: Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites
Ma Luo, University of Manitoba, Canada
Title: Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by live attenuated SIV
Qingsheng Li, University of Nebraska-Lincoln, USA
Title: TAT, the forgotten target that could help to cure from HIV
Erwann P Loret, ETRAV Laboratory, France
Title: Community engagement during the Ebola vaccine trial in Guinea
Godwin Enwere, World Health Organization, Switzerland
Title: Pre-clinical toxicology considerations in vaccine
Nabil Al-Humadi, Food and Drug Administration, USA

Lunch Break

Title: Codon harmonization, a step beyond optimization to capture the natural rhythm of protein translation
Bettina Werle, Bioaster, France
Title: Development of lipid based oral vaccine formulations
Sarah Margaret Hook, University of Otago, New Zealand
Title: Viral vectored genetic vaccines: Current status and future perspectives
Antonella Folgori, Reithera SRL, Italy
Title: Active immunization against proprotein convertase subtilisin/kexin type 9 (PCSK9): A new strategy to control hyperlipidemia
Gunther Staffler, AFFiRiS AG, Austria
Title: Development of a production and purification platform for virus like particles (VLP) vaccine candidates: A case study
Anissa Boumlic-Courtade, Merck Life Science, France
Title: MATS: Global coverage estimates for 4CMenB, a novel multi-component meningococcal B vaccine
Duccio Medini, GSK Vaccines, Italy

Networking & Refreshments Break

Title: Implementing a randomized control trial (RCT) in the context of an Ebola epidemic
Godwin Enwere, World Health Organization, Switzerland
Title: Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge
Peter Burkhard, Alpha-O Peptides AG, Switzerland
Title: Plant expression platforms for vaccine production
Kathleen Hefferon, Cornell University, USA

Title: What do Lebanese women know about cervical cancer and human papillomavirus prevention? A report on awareness levels in urban communities
Jacques Choucair, Saint Joseph University, Lebanon

Young Researchers Forum

Title: Isolation and characteristics identification of bovine rotaviruses from vaccinated dairy calves in Morocco
Ennima Imane , University Mohammed V of Rabat, Morocco
Title: Bluetongue virus (BTV) serological survey and evidence of emergent BTV-8 serotype in Morocco
Kamar Drif, Institut Agronomique et Veterinaire Hassan II, Morocco
Title: Evaluation of the protection conferred by an attenuated vaccine (Mass-type H120) of avian infectious bronchitis against a new emerging Italy 02 genotype in Moroccan broiler chickens
Khadija Khataby, University Hassan II of Casablanca, Morocco

Panel Discussion

Day 2 June 17, 2016

Appia

Keynote Forum

Title: Towards affordable conjugate vaccines: Efficient chemistry and low cost carrier protein
Andrew Lees, Fina Biosolutions LLC, USA

Title: Human vaccines and vaccination for non-infectious diseases
Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy

Networking & Refreshments Break

Title: Challenges and dilemmas about vaccines against the herpesviruses : The case of EBV
Emmanuel Drouet, Université Grenoble-Alpes, France

Track 7: Vaccines against Infectious diseases
Track 8: Viral Vaccines
Track 9: Bacterial Vaccines
Track 10: Childhood Vaccines
Track 11: Hepatitis Vaccines
Track 12: Toxoid Vaccines

Session Chairs: Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy
Andrew Lees, Fina Biosolutions LLC, USA

Session Introduction

Title: Rapid development of an oral Zika virus vaccine
Sean N Tucker, Vaxart Inc., USA
Title: Preclinical development of HeV-sG as a vaccine and m102.4 as a post exposure prophylaxis against henipavirus infections
Timothy R Fouts, Profectus Bio-Sciences, USA
Title: Measles: Need for continued vaccination and novel vaccines post virus eradication
S Louise Cosby, Agri-Food and Biosciences Institute, UK
Title: Evaluation of genetic stability of transgenes in vaccine
Ali Azizi, Sanofi Pasteur, Canada
Title: Process development for pneumococcal protein vaccines based on recombinant pneumococcal surface protein A (PspA) and hybrids of PspA and pneumolysin toxoid
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

Lunch Break

Title: The key person influences flu vaccination among health workers: Perspective study of social network
Xiaoning Hao, China National Health Development Research Center, China
Title: Pneumococcal conjugate vaccine: Use of pneumococcal surface protein A (PspA) as carrier
Giovana Cappio Barazzone, Instituto Butantan, Brazil
Title: Construction and immunological study on recombinant multi-epitope adenovirus vaccine for influenza virus
Hui-jun Lu, Changchun Veterinary Institute of CAAS, China
Title: Pneumococcal inactivated whole cell vaccine: Development of the production process
Viviane Maimoni Goncalves, Instituto Butantan, Brazil
Title: Knowledge, attitude and practices and influencing factors related to seasonal influenza vaccination among healthcare workers in Qingdao, China, 2013-14: A prospective cohort study
Xiaoning Hao, China National Health Development Research Center, China
Title: Polio outbreak review in the Middle East and polio immunization mop-up campaigns in the Lebanese/Syrian refugees' context and post campaign results
Randa Hamadeh, Ministry of Public Health, Lebanon

Networking & Refreshments Break 15:20-15:40 @ Foyer area

Title: Prevalence of tuberculin negativity after BCG vaccination in the under five Saudi children and the need for revaccination
Fahad Saleh Al-Tayyeb, King Abdulaziz Medical City, KSA
Title: Vaccination of hepatitis B in healthy adults: Effect of sex and age, two protocols of revaccination in non-responders
Jacques Choucair, Saint Joseph University, Lebanon

Panel Discussion

Breakout

Cassia Meeting Room

Workshop on
Revisiting HIV inactivation, elite controllers, immunogenetics and HIV therapeutic vaccines

Session Chairs: **Barbara Ensoli,** National AIDS Center-Istituto Superiore di Sanità, Ital
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

Title: Expanding the findings of RV144 to South Africa: P5 initiative
Glenda Gray, South African Medical Research Council, South Africa

Title: Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross-clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Africa
Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy

Networking & Refreshments Break

Title: Current strategies for HIV remission: The role of therapeutic vaccines
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

Title: Synthetic DNA vaccines for difficult mucosal viruses including HIV
Jean D. Boyer, Inovio Pharmaceuticals Inc., USA

Title: Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine
Adan Rios, PhotoImmune Biotechnology Inc., USA

Discussion

Lunch Break

Session Chairs: **Marc H.V. Van Regenmortel,** Biotechnology School of the University of Strasbourg, France
Eric Sandstrom, Karolinska Institutet, Sweden

Title: HIV vaccine development: Is a moral wrong occurring?
Mike King, University of Otago, New Zealand

Title: Reverse HIV vaccinology failed because it has no sound theoretical basis in the case of this virus
Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France

Title: HIV replication is suppressed by CD8+T- regulatory cells in elite controllers
Jean Marie Andrieu, Paris-Descartes University, France

Title: Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+T-cell HIV suppressive activity
Eric Sandstrom, Karolinska Institutet, Sweden

Networking & Refreshments Break

Title: Multiple immunogenetic aspects in susceptibility to HIV-1 infection progression toward AIDS and rational vaccine design
Massimo Amicosante, University of Rome, Italy

Workshop Discussion

Poster Presentations

EVACC 01 **Role of insulin like growth factor-1 derived from macrophages in an influenza vaccine induced humoral immune response**
Jae-Hwan Nam, Catholic University of Korea, South Korea

EVACC 02 **Visualization of immune response to hepatitis B vaccination by in vivo small animal imaging**
Hyewon Youn, Seoul National University, South Korea

EVACC 03 **Development immunogen for protection against PRRSV infection using Korean isolates ORF5 protein expression using baculovirus expression system**
Sun Shin Yi, Soonchunhyang University, South Korea

EVACC 04 **Vaccine potentials of excretory-secretory antigens of 4 week old juveniles against *Fasciola gigantica* in mice**
Narin Changklungmoa, Burapha University, Thailand

EVACC 05 **Vaccine potentials of recombinant mature cathepsin L1H against *Fasciola gigantica* in mice**
Pornanan Kueakhai, Burapha University, Thailand

EVACC 06 **Characterization and vaccination of the cytosolic *Fasciola gigantica* superoxide dismutase**
Wipaphorn Jaikua, Mahidol University, Thailand

EVACC 07 **Study for manufacture and establishment of 1st national standard material for cell derived Japanese encephalitis vaccine (Beijing strain)**
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, Korea

EVACC 08 **Histone deacetylase 10 (HDAC 10) deacetylates Foxp3 and modulates its stability**
Suna Gu, Chonbuk National University, Republic of Korea

EVACC 09 **In silico design of epitope based peptide vaccine against virulent strains of HN-Newcastle disease virus (NDV) in poultry species**
Marwa Mohamed Osman, Africa City of Technology, Sudan

Day 3

Appia

Track 13: DNA Vaccines
Track 14: Vaccine Safety and Efficacy
Track 15: Vaccine Adjuvants
Track 16: Tuberculosis Vaccines
Track 17: Vaccination for Pregnant Women
Track 18: Human Preventive and Therapeutic Vaccines

Session Chair: Emmanuel Drouet, Université Grenoble-Alpes, France
Session Co-Chair: Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Session Introduction

Title: Vaccines for pregnant women - challenges and opportunities for harmonized safety monitoring
Sonali Kochhar, Global Healthcare Consulting, India
Title: Exploiting a high dose murine challenge model for HSV to identify potential DNA prime subunit boost vaccine strategies that could be translated to human clinical trials
Timothy R Fouts, Profectus Biosciences Inc., USA

Networking & Refreshments Break

Title: Operational experience and lessons learned on influenza vaccination post authorization safety studies
Ombretta Palucci, Quintiles, Switzerland
Title: Post-marketing surveillance of BCG vaccination
Ruwen Jou, Tuberculosis Research Center at Centers for Disease Control, Taiwan
Title: Novel vaccine adjuvants for animal infectious diseases
Jishu Shi, Kansas State University, USA
Title: Emerging market challenges: Development of a thermostable and immunologically active solid HPV vaccine formulation
Ramesh Chintala, Merck & Co. Inc., USA

Lunch Break

Title: Immunogenicity of VLP forming baculoviral DNA vaccine
Young Bong Kim, Konkuk University, Republic of Korea
Title: Targeting TLR9 and TLR21 to develop vaccine adjuvant for different species
Tsung-Hsien Chuang, National Health Research Institutes, Taiwan
Title: Therapeutic vaccines for treatment of allergic and autoimmune diseases
Zhikang Peng, University of Manitoba, Canada
Title: Therapeutic vaccines against chronic hepatitis-B virus and related complications
Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Panel Discussion & Closing Ceremony

Bookmark your dates

18th International Conference on

Vaccine Adjuvatns Delivery Technologies

July 27-28, 2017 Chicago, USA

e-mail: mailto:vaccinedelivery@vaccineconference.com" vaccinedelivery@vaccineconference.com

Website: http://vaccinedelivery.conferenceseries.com/

Conference Series LLC
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
america@conferenceseries.com

Conference Series Ltd.
Traian Str., No.61, Constanta 900720,
Romania, Tel: 0805-080048
Heathrow Stockley Park Lakeside
House, 1 Furzeground Way, Heathrow,
UB11 1BD, United Kingdom
europe@conferenceseries.com

OMICS International
6th Floor, North Block, Divyasree
Building, Raidurg Hyderabad,
Telangana, INDIA-500032
Tel: +91-40-33432300
asia.pacific@conferenceseries.com

Toll free
USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048